Baloxavir marboxil: Difference between revisions
Undid revision 934810152 by 2601:246:C700:19D:A893:D336:57FE:E91C (talk) The content from the FDA is public domain |
Undid revision 934811137 by Whywhenwhohow (talk) You misunderstand—public domain does not mean material can be plagiarised, and used without paraphrasing or quoting. PLEASE, enter into discussion at Doc James Talk page, and do not continue to edit war. |
||
| Line 116: | Line 116: | ||
== Approval == |
== Approval == |
||
| ⚫ | The FDA approved baloxavir marboxil based on evidence of its benefits and side effects from two clinical trials in adult and pediatric patients with uncomplicated influenza, Trial 1/1518T0821 and Trial 2/NCT02954354, involving 1119 patients.<ref name="FDA Snapshot">{{cite web | author = FDA Staff | date = July 23, 2019 | title=Drug Trial Snapshot: Xofluza | website=U.S. [[Food and Drug Administration]] (FDA) | url=http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-xofluza | access-date=7 January 2020}}</ref> |
||
| ⚫ | Baloxavir marboxil was approved for sale in Japan in February 2018.<ref>{{cite press release|url=http://www.publicnow.com/view/7E9FBF87835EEBAC31508CC4E1F96D3D77D54C0A|title=Xofluza (Baloxavir Marboxil) Tablets 10mg/20mg Approved For The Treatment Of Influenza Types A And B In Japan|date=23 February 2018|via=www.publicnow.com|publisher=[[Shionogi|Shionogi & Co., Ltd.]]}}</ref> On October 24, 2018, the U.S. [[Food and Drug Administration]] (FDA) approved it for the treatment of acute uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours.<ref name=FDA/> |
||
| ⚫ | Baloxavir marboxil was approved for sale in Japan in February 2018.<ref>{{cite press release|url=http://www.publicnow.com/view/7E9FBF87835EEBAC31508CC4E1F96D3D77D54C0A|title=Xofluza (Baloxavir Marboxil) Tablets 10mg/20mg Approved For The Treatment Of Influenza Types A And B In Japan|date=23 February 2018|via=www.publicnow.com|publisher=[[Shionogi|Shionogi & Co., Ltd.]]}}</ref> On October 24, 2018, the U.S. [[Food and Drug Administration]] (FDA) approved it for the treatment of acute uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours.<ref name=FDA/> The FDA application of baloxavir marboxil was granted [[priority review]] in the United States, and approval of Xofluza was granted to [[Shionogi]] & Co., Ltd. in October 2019.<ref name=FDA/>{{verification needed}} Specifically, the FDA approved the use of Xofluza for people at high risk of developing influenza-related complications.<ref>{{cite press release | title=Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications | publisher=[[Genentech]] | via=Business Wire | date=17 October 2019 | url=https://www.businesswire.com/news/home/20191017005525/en | archive-url=https://web.archive.org/web/20191024061608/https://www.businesswire.com/news/home/20191017005525/en | archive-date=24 October 2019 | url-status=live | access-date=23 October 2019}}</ref> |
||
| ⚫ | The FDA approved baloxavir marboxil based on evidence from two clinical trials |
||
The benefit and side effects of baloxavir marboxil were evaluated in two clinical trials in adult and pediatric patients with uncomplicated influenza.<ref name="FDA Snapshot" /> |
|||
Trial 1 enrolled adult patients 20 to 64 years old who had symptoms of flu for no more than 48 hours.<ref name="FDA Snapshot" /> Patients were assigned to receive either a single dose of baloxavir marboxil or placebo by mouth.<ref name="FDA Snapshot" /> Neither the patients nor the health care providers knew which treatment was being given until after the trial was completed.<ref name="FDA Snapshot" /> The benefit of baloxavir marboxil was assessed based on the time patients reported all seven symptoms (cough, sore throat, nasal congestion, headache, fever, muscle pain, and tiredness) gone or mild for at least 21.5 hours, comparing the baloxavir marboxil and placebo groups.<ref name="FDA Snapshot" /> |
|||
Trial 2 enrolled adult and adolescent patients 12 to 64 years old who had symptoms of flu for not more than 48 hours.<ref name="FDA Snapshot" /> Adult patients were assigned to receive either baloxavir marboxil on Day 1 followed by placebo on Days 2 – 5, placebo as a twice daily dose by mouth for 5 days, or oseltamivir (a medication used to treat and prevent influenza) by mouth twice a day for 5 days.<ref name="FDA Snapshot" /> Neither the patients nor the health care providers knew which treatment was being given until after the trial was completed.<ref name="FDA Snapshot" /> The benefit of baloxavir marboxil was assessed based on the time patients reported all seven symptoms (cough, sore throat, nasal congestion, headache, fever, muscle pain, and tiredness) gone or mild for at least 21.5 hours, comparing the baloxavir marboxil and placebo groups.<ref name="FDA Snapshot" /> |
|||
The application of baloxavir marboxil was granted [[priority review]] and approval of Xofluza was granted to Shionogi & Co., Ltd.<ref name=FDA/> |
|||
==References== |
==References== |
||
Revision as of 16:52, 8 January 2020
 | This article needs attention from an expert in Medicine or Chemistry. The specific problem is: the article fails to paint a complete picture of what is known about the benefits and drawbacks of this medication as of this date, and says nothing about the discovery, or the agent's chemistry; update of the 10 year-old science is needed. (January 2020) |
 | |
| Clinical data | |
|---|---|
| Trade names | Xofluza |
| Other names | S-033188/S-033447 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618062 |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H23F2N3O7S |
| Molar mass | 571.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B. It is taken as a single dose by mouth. It may reduce the duration of flu symptoms by about a day.
It was approved for medical use in the United States in 2018. It was developed by Shionogi Co., a Japanese pharmaceutical company, and Roche AG.[1]
Medical use
As of September 2018, in the only report of a phase III randomized, controlled trial, baloxavir reduced the duration of influenza symptoms of otherwise healthy outpatients by about one day compared to a placebo treatment group, and comparable to what was seen for a oseltamivir treatment group. On the first day after baloxavir was started in its treatment group of patients, viral loads decreased more than in patients in either the oseltamivir or placebo groups; however, after five days, the effect on viral load of the single dose of baloxavir was indistinguishable from the effect observed following the complete, 5-day regimen of oseltamivir in its treatment group.[2][verification needed]
Resistance
In 2.2% of baloxavir recipients in the phase II trial and in about 10% of baloxavir recipients in the phase III trial, the infecting influenza strain had acquired resistance to the drug, due to variants of the polymerase protein displaying substitutions of isoleucine-38, specifically, the I38T, I38M, or I38F mutations.[2]
Side effects
Common side effects following the single dose administration of baloxavir were diarrhea and bronchitis.[3][better source needed] Adverse events were reported in 21% of people who received baloxavir, 25% of those receiving placebo, and 25% of oseltamivir.[2]
Mechanism of action
| This section has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small}
Baloxavir marboxil is an influenza therapeutic agent, specifically, an enzyme inhibitor targeting the influenza virus' cap-dependent endonuclease activity,[citation needed] one of the activities of the virus polymerase.[citation needed] In particular, it inhibits a process known as cap snatching,[citation needed] wherein virus derives short, capped primers from host cell RNA transcripts, using them for polymerase-catalyzed synthesis of its needed viral mRNAs.[4][non-primary source needed] A polymerase subunit binds to the host pre-mRNAs at their 5′-caps, then the polymerase's endonuclease activity catalyzes its cleavage "after 10–13 nucleotides".[4][non-primary source needed] As such, its mechanism is distinct from neuraminidase inhibitors such as oseltamivir and zanamivir.[citation needed]
Approval
The FDA approved baloxavir marboxil based on evidence of its benefits and side effects from two clinical trials in adult and pediatric patients with uncomplicated influenza, Trial 1/1518T0821 and Trial 2/NCT02954354, involving 1119 patients.[5]
Baloxavir marboxil was approved for sale in Japan in February 2018.[6] On October 24, 2018, the U.S. Food and Drug Administration (FDA) approved it for the treatment of acute uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours.[3] The FDA application of baloxavir marboxil was granted priority review in the United States, and approval of Xofluza was granted to Shionogi & Co., Ltd. in October 2019.[3][verification needed] Specifically, the FDA approved the use of Xofluza for people at high risk of developing influenza-related complications.[7]
References
- ^ Branswell, Helen (27 June 2018). "A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S." STAT.
- ^ a b c Hayden FG, Sugaya N, Hirotsu N, et al. (September 2018). "Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents". N. Engl. J. Med. 379 (10): 913–923. doi:10.1056/NEJMoa1716197. PMID 30184455.
- ^ a b c "FDA approves new drug to treat influenza". U.S. Food and Drug Administration (FDA) (Press release). 24 October 2018. Archived from the original on 24 October 2019. Retrieved 23 October 2019.
- ^ a b Dias A, Bouvier D, Crépin T, et al. (April 2009). "The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit". Nature. 458 (7240): 914–8. Bibcode:2009Natur.458..914D. doi:10.1038/nature07745. PMID 19194459.
- ^ FDA Staff (23 July 2019). "Drug Trial Snapshot: Xofluza". U.S. Food and Drug Administration (FDA). Retrieved 7 January 2020.
- ^ "Xofluza (Baloxavir Marboxil) Tablets 10mg/20mg Approved For The Treatment Of Influenza Types A And B In Japan" (Press release). Shionogi & Co., Ltd. 23 February 2018 – via www.publicnow.com.
- ^ "Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications" (Press release). Genentech. 17 October 2019. Archived from the original on 24 October 2019. Retrieved 23 October 2019 – via Business Wire.
Further reading
- Mushtaq, Ammara (1 December 2018). "Spotlight: Baloxavir, Game-Changer or Much Ado About Nothing?". The Lancet:Respiratory Medicine. 6 (12): 903f. doi:10.1016/S2213-2600(18)30469-7. Retrieved 7 January 2020. Recent short review characterizing strengths and weaknesses of the new medication, including the matters of single dose and selected resistance.
- Rana, Preetika (10 February 2018). "Experimental Drug Promises to Kill the Flu Virus in a Day". The Wall Street Journal. Retrieved 7 January 2020. An early report in the business news, overstating the claim and over-elevating the expectations for the treatment.
External links
- "Baloxavir marboxil". Drug Information Portal. U.S. National Library of Medicine.
- "Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil)". U.S. Food and Drug Administration (FDA). 7 December 2018.</ref>
